睿智医药
(300149)
| 流通市值：34.07亿 | | | 总市值：34.13亿 |
| 流通股本：4.99亿 | | | 总股本：5.00亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 718,525,731.65 | 465,164,579.93 | 234,594,741.64 | 1,138,365,803 |
| 营业收入 | 718,525,731.65 | 465,164,579.93 | 234,594,741.64 | 1,138,365,803 |
| 二、营业总成本 | 774,216,447.7 | 525,102,424.42 | 263,463,408.41 | 1,198,434,734.47 |
| 营业成本 | 580,392,041.96 | 389,334,679.48 | 193,136,476.58 | 843,125,473.18 |
| 税金及附加 | 4,077,279.77 | 3,136,583.56 | 970,462.1 | 5,669,744.54 |
| 销售费用 | 28,332,227.32 | 21,080,953.73 | 10,997,471.42 | 45,596,590.27 |
| 管理费用 | 108,034,303.98 | 77,678,203.2 | 39,205,533.26 | 212,549,928.34 |
| 研发费用 | 45,275,069.93 | 32,166,317.85 | 16,901,112.25 | 77,468,257.76 |
| 财务费用 | 8,105,524.74 | 1,705,686.6 | 2,252,352.8 | 14,024,740.38 |
| 其中:利息费用 | 2,911,402.21 | 2,139,821.81 | 1,061,819.9 | 31,299,155.13 |
| 其中:利息收入 | 7,167,883.24 | 4,664,618.03 | 2,278,712.7 | 14,793,659.48 |
| 加:公允价值变动收益 | 1,648.56 | 0 | - | 0 |
| 加:投资收益 | 7,301,977.95 | 2,500,977.33 | 1,727,374.35 | -922,396.63 |
| 净敞口套期收益 | - | 0 | - | - |
| 资产处置收益 | 3,621,788.88 | 48,133.97 | - | -412.39 |
| 资产减值损失(新) | -13,627,814.85 | -3,382,513.36 | -1,936,377.65 | -877,869,899 |
| 信用减值损失(新) | -14,756,509.91 | -11,877,023.49 | 272,295.47 | -6,073,572.7 |
| 其他收益 | 6,591,864.4 | 2,975,994.68 | 1,536,809.63 | 8,571,490.29 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -66,557,761.02 | -69,672,275.36 | -27,268,564.97 | -936,363,721.9 |
| 加:营业外收入 | 29,117.39 | 20,154.16 | 67,985.42 | 815,880 |
| 减:营业外支出 | 510,060.41 | 405,325.86 | 239,553.36 | 4,218,098.4 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -67,038,704.04 | -70,057,447.06 | -27,440,132.91 | -939,765,940.3 |
| 减:所得税费用 | -5,256,354.55 | -7,077,244.96 | -1,940,382.03 | -22,826,973.86 |
| 六、净利润 | -61,782,349.49 | -62,980,202.1 | -25,499,750.88 | -916,938,966.44 |
| 持续经营净利润 | -61,782,349.49 | -62,980,202.1 | -25,499,750.88 | -916,938,966.44 |
| 归属于母公司股东的净利润 | -61,667,008.36 | -62,906,492.74 | -25,460,550.66 | -916,752,668.84 |
| 少数股东损益 | -115,341.13 | -73,709.36 | -39,200.22 | -186,297.6 |
| (一)基本每股收益 | -0.12 | -0.13 | -0.05 | -1.84 |
| (二)稀释每股收益 | -0.12 | -0.13 | -0.05 | -1.84 |
| 八、其他综合收益 | -9,433,940.61 | -1,144,800.81 | 1,875,939.7 | 7,823,267.39 |
| 归属于母公司股东的其他综合收益 | -9,433,940.61 | -1,144,800.81 | 1,875,939.7 | 7,823,267.39 |
| 九、综合收益总额 | -71,216,290.1 | -64,125,002.91 | -23,623,811.18 | -909,115,699.05 |
| 归属于母公司股东的综合收益总额 | -71,100,948.97 | -64,051,293.55 | -23,584,610.96 | -908,929,401.45 |
| 归属于少数股东的综合收益总额 | -115,341.13 | -73,709.36 | -39,200.22 | -186,297.6 |
| 公告日期 | 2024-10-30 | 2024-08-30 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |